Profile data is unavailable for this security.
About the company
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.
- Revenue in USD (TTM)448.39m
- Net income in USD-16.54m
- Incorporated2018
- Employees862.00
- LocationOrganogenesis Holdings Inc85 Dan RdCANTON 02021-2810United StatesUSA
- Phone+1 (781) 575-0775
- Fax+1 (302) 655-5049
- Websitehttps://investors.organogenesis.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biomea Fusion Inc | 0.00 | -139.65m | 379.48m | 112.00 | -- | 3.65 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Voyager Therapeutics Inc | 143.77m | 9.02m | 383.91m | 162.00 | 45.88 | 1.14 | 27.64 | 2.67 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 384.47m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 387.45m | 25.00 | -- | -- | -- | 235.53 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Grail Inc | 109.74m | -2.88bn | 404.57m | 1.37k | -- | 0.1501 | -- | 3.69 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
SAGE Therapeutics Inc | 97.24m | -445.67m | 405.37m | 487.00 | -- | 0.6438 | -- | 4.17 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Organogenesis Holdings Inc | 448.39m | -16.54m | 408.33m | 862.00 | -- | 1.55 | -- | 0.9107 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Taysha Gene Therapies Inc | 12.87m | -114.34m | 411.94m | 52.00 | -- | 3.72 | -- | 32.00 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Prime Medicine Inc | 591.00k | -217.44m | 421.31m | 234.00 | -- | 2.14 | -- | 712.87 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Verve Therapeutics Inc | 20.65m | -192.65m | 423.12m | 255.00 | -- | 0.7742 | -- | 20.49 | -2.59 | -2.59 | 0.275 | 6.46 | 0.032 | -- | 8.05 | 80,972.55 | -29.87 | -- | -31.67 | -- | -- | -- | -933.03 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Larimar Therapeutics Inc | 0.00 | -58.34m | 424.31m | 42.00 | -- | 2.01 | -- | -- | -1.11 | -1.11 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -33.44 | -42.22 | -36.41 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Compass Pathways PLC (ADR) | 0.00 | -139.21m | 424.69m | 186.00 | -- | 1.88 | -- | -- | -2.30 | -2.30 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -57.01 | -40.85 | -61.38 | -44.48 | -- | -- | -- | -- | -- | -52.52 | 0.1151 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Aura Biosciences Inc | 0.00 | -80.69m | 432.57m | 88.00 | -- | 2.26 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Foghorn Therapeutics Inc. | 35.19m | -86.45m | 433.22m | 116.00 | -- | -- | -- | 12.31 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
Contineum Therapeutics Inc | 0.00 | -31.45m | 437.30m | 31.00 | -- | 2.01 | -- | -- | -1.24 | -1.24 | 0.00 | 8.46 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 437.95m | 1.22k | -- | 5.16 | -- | 2.38 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 11.45m | 8.63% |
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 9.57m | 7.22% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.44m | 3.35% |
Assenagon Asset Management SA (Germany)as of 30 Jun 2024 | 3.98m | 3.00% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.46m | 2.61% |
Acadian Asset Management LLCas of 30 Jun 2024 | 3.07m | 2.32% |
DWS Investments (UK) Ltd.as of 31 Mar 2024 | 2.51m | 1.89% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.88m | 1.42% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.75m | 1.32% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.45m | 1.10% |